Abstract：Paragangliomas(PGL) is a rare neuroendocrine tumor in clinic, and the etiology of PGL is not clear at present. PGL is most likely to occur in abdomen and pelvis, and the majority of tumors are benign with the malignant incidence of 33% approximately. In this study, we systematically reviewed relative and updated literatures about abdominal PGL in recent years, and discussed the diagnosis and treatment methods comprehensively.
[1] 朱庆国,朱伟,叶烈夫,等.双侧肾上腺嗜铬细胞瘤并副神经节瘤8例临床诊治.微创泌尿外科杂志,2015,4(3):172-175. [2] Brove EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev, 1994,15(3):356-368. [3] Woolen S, Gemmete JJ. Paragangliomas of the Head and Neck. Neuroimag Clin N Am, 2016,26(2):259-278. [4] Pappachan JM, Raskauskiene D, Sriraman R, et al. Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep, 2014,16(7):442. [5] Baysal BE, Willett-brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet, 2002,39(3):178-183. [6] Galan SR, Kann PH. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol, 2013,78(2):165-175. [7] Persu A, Lannoy N, Maiter D, et al. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update. Horm Metab Res, 2012,44(5):349-353. [8] 孙立安,张永康,王国民,等.嗜铬细胞瘤的诊治(附85例报告).中华泌尿外科杂志,1999,20(11):647-649. [9] Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer, 2014,135(11):2711-2720. [10] Eisenhofer G. Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep, 2012,14(2):130-137. [11] Ezzat abdel-Aziz T, Prete F, Conway G, et al. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes. J Surg Oncol, 2015,112(5):486-491. [12] Subramanyam S, Kreisberg RA. Pheochromocytoma: a cause of ST-segment elevation myocardial infarction, transient left ventricular dysfunction, and takotsubo cardiomyopathy. Endocr Pract, 2012,18(4):e77-80. [13] Varghese RT, John AM, Paul TV. Catecholamine induced cardiomyopathy in pheochromocytoma. Indian J Endocrinol Metab, 2013,17(4):733-735. [14] Karagiannis A, Mikhailidis DP, Athyros VG, et al. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer, 2007,14(4):935-956. [15] 李鲁滨,沈来根.腹膜后副神经节瘤的诊治进展.国际外科学杂志,2006,33(6):440-443. [16] Conzo G, Pasquali D, Colantuoni V, et al. Current concepts of pheochromocytoma. Int J Surg, 2014,12(5):469-474. [17] Moraitis AG, Martucci VL, Pacak K. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma. Endocr Pract, 2014,20(2):176-187. [18] Gimenez-roqueplo AP.Pheochromocytoma and paraganglioma. Rev Prat, 2015,65(6):826-830. [19] Van berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol, 2014,170(3):R109-119. [20] Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev, 2003,24(4):539-553. [21] Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev, 2004,56(3):331-349. [22] Chen H, Sippel R S, O'dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas, 2010,39(6):775-783. [23] Kiernan CM, Solorzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. Surg Oncol Clin N Am, 2016,25(1):119-138. [24] Yao R, Hu W, Qian M, et al. Correlation between CT image presentations and biochemical indexes in adrenal adenomas and pheochromocytomas. Nan Fang Yi Ke Da Xue Xue Bao, 2015,35(12):1792-1796. [25] Leung K, Stamm M, Raja A, et al. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol, 2013,200(2):370-378. [26] 马霄虹,戴景蕊,张红梅,等.腹膜后副神经节瘤的临床及CT表现与病理对照研究.医学影像学杂志,2007,17(11):1225-1258. [27] Zdrojowy-welna A, Bednarek-Tupikowska G. Challenges in the diagnosis of pheochromocytoma and paraganglioma syndrome. Neuro Endocrinol Lett, 2014,35(5):355-358. [28] Rufini V, Treglia G, Perotti G, et al. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas. Hormones, 2013,12(1):58-68. [29] Lalloo F. Diagnosis and Management of Hereditary Phaeochromocytoma and Paraganglioma. Recent results Cancer Res, 2016,205:105-124. [30] Boerman OC, Oyen WJ, Corestens FH. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med, 2000,30(3):195-208. [31] Slooter GD, Mearadji A, Breeman WA, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg, 2001,88(1):31-40. [32] Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA, 2004,292(8):943-951. [33] Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res, 2003,63(17):5615-5621. [34] Pahwa M, Pahwa AR, Batra R, et al. Robotic assisted laparoscopic adrenalectomy: Initial experience from a tertiary care centre in India. J Minim Access Surg, 2015,11(1):83-86. [35] Pullerits J, Ein S, Balfe JW. Anaesthesia for phaeochromocytoma. Can J Anaesth, 1988,35(5):526-534. [36] Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth, 2002,16(3):359-369. [37] Weingarten TN, Cata JP, O'hara JF, et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology, 2010,76(2):508.e6-11. [38] Fishbein L. Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment. Hematol Oncol Clin North Am, 2016,30(1):135-150. [39] Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep, 2013,15(4): 356-371. [40] Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol, 1992,147(1):1-10. [41] Plouin PF, Fitzgerald P, Rich T, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res, 2012,44(5):390-399. [42] Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose 131 I metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol, 2009,27(25):4162-4168. [43] Ayala-ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer, 2012,118(11):2804-2812. [44] Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab, 2009,94(1):5-9. [45] Favier J, Igaz P, Burnichon N, et al. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol, 2012, 23(1):34-42. [46] Ayala-ramirez M, Palmer JL, Hofmann MC, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab, 2013,98(4):1492-1497. [47] Teno S, Tanabe A, Nomura K, et al. Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma. Endocr J, 1996,43(5):511-516. [48] Amar L, Servais A, Gimenez-roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab, 2005,90(4):2110-2116.
